TruAlt Bioenergy: IPO Proceeds Utilization Report for Q3 FY26
TruAlt Bioenergy Limited's IPO proceeds utilization report for Q3 FY26 shows ₹750 crore gross proceeds, with ₹519.63 crore utilized as of December 31, 2025. Net proceeds of ₹657.04 crore were allocated to capital expenditure, working capital, and general corporate purposes, including subsidiary investments.
This announcement is a regulatory filing detailing the past utilization of IPO funds. It does not contain new strategic information, financial results, or future guidance that would significantly impact the company's stock price or investor outlook.
The report is a routine monitoring agency submission detailing the utilization of IPO proceeds. It confirms that the utilization is in line with the offer document, with no adverse findings or deviations reported. Therefore, the sentiment is neutral.
TruAlt Bioenergy Limited has submitted its Monitoring Agency Report for the quarter ended December 31, 2025, detailing the utilization of proceeds from its Initial Public Offer (IPO). The report, issued by Crisil Ratings Limited, was reviewed and taken on record by the Audit Committee and Board of Directors on February 2 and 3, 2026, respectively.
The company's IPO, which occurred from September 25 to September 29, 2025, raised ₹750.00 crore in gross proceeds. After deducting issue expenses of ₹92.96 crore, the net proceeds amounted to ₹657.04 crore. These net proceeds were allocated towards capital expenditure for setting up multi-feed stock operations (₹150.68 crore), funding working capital requirements (₹425.00 crore), and general corporate purposes (₹81.36 crore).
As of December 31, 2025, the total unutilized amount from the IPO proceeds was ₹230.37 crore. Of the ₹657.04 crore in net proceeds, ₹473.34 crore had been utilized towards the stated objects, and ₹46.29 crore towards issue expenses, totaling ₹519.63 crore utilized from the gross proceeds of ₹750.00 crore. The unutilized funds include ₹183.70 crore for the objects and ₹46.67 crore for issue expenses.
Specifically, ₹140.13 crore was utilized for capital expenditure, ₹263.22 crore for working capital, and ₹69.99 crore for general corporate purposes. The utilization for general corporate purposes included ₹8.43 crore for acquiring a 51% stake in Trualt Gas Private Limited and ₹20.00 crore for investment in the same subsidiary. The remaining funds for general corporate purposes were used for company expenses and GST payments.
The company reported no deviations from the objects disclosed in the Offer Document, and no material deviations requiring shareholder approval were noted. There were no delays in the implementation of the objects.
What to do with a filing like this
TruAlt Bioenergy Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by TruAlt Bioenergy Limited. Read the original for the full detail.